Identification of LB-60-OF61
The MYC (c-MYC) oncogene drives oncogenic transformation of cells and thus contributes to the genesis of many human cancers 1 . As increased expression and amplification of the MYC gene are a hallmark of oncogenic transformation we aimed at identifying compounds that inhibit proliferation of cells with high MYC activity. For this purpose, we selected four cell lines with high MYC activity and cellular MYC dependency and four cell lines with low MYC levels and low dependency on MYC. This cell panel was then used to screen for compounds that selectively caused cytotoxicity in the MYC high, MYC-dependent group only. Compounds were tested in 8-point dose-response fashion and viability was assessed by CellTiter-Glo assay according to the manufacturer's instructions (#G7573, Promega). Compound LB-60-OF61 was prioritized based on its greater selectivity toward the four MYC high/dependent cells lines (IC 50 < 100 nM) versus the low/independent cell lines ( IC 50 >1 µM). IC 50 stands for the concentration at which 50% growth inhibition was observed.
Cell lines for the screen were selected as follows: MYC expression was based on both quantitative PCR (qPCR) and protein quantification by western blot analysis (data not shown). Dependency was 
Derivatization of LB-60-OF61
Compound LB-60-OF61 is a deazapurine chemotype identified in the MYC cancer screen described above. Early structure-activity relationship (SAR) studies revealed the importance of the 3-pyridyl pendant portion of the compound. Subtle changes to this portion of the molecule were detrimental to compound activity so the 3-pyridyl substitution was retained for subsequent SAR optimization.
Removal or reduction of the nitrile group preserved the MYC dependent cytotoxicity. This resulted in the identification of ZA-87-IW08, a potent molecule that retains MYC dependent cytotoxicity. ND-37-YO30 and other derivatives with bulkier acyl groups (e.g. R = O-tButyl) demonstrated a general tolerance for large substituents at this position and therefore validated compound design for immobilization onto affinity beads at this position.
Determination of LB-60-OF61 potency
To correctly dose compounds for the chemogenomic profiling experiment, cytotoxic effects of LB-60-OF61, ZA-87-IW08 and ND-37-YO30 on HCT116 cells (#CCL-247, ATCC) were assessed in 384 well plates by seeding 1500 cells/well and adding serially diluted compound in a dose range from 0.37 nM to 20 µM. The compound solvent dimethyl sulfoxide (DMSO) was normalized to 0.2 %. 72
hours after compound addition cell viability was measured using the CellTiter-Glo assay according to the manufacturer's instructions (#G7573, Promega). Data was analyzed and IC 50 s (compound concentration at which 50% inhibition was observed) calculated using the logistic regression curve fit analysis of the Tibco Spotfire package (version 6.5.3, TIBCO Software Inc.). As the LB-60-OF61
inhibition curve was very steep it was difficult to pinpoint the IC 30 and IC 50 concentrations. We thus repeated testing in 6 well plates, seeding 100'000 HCT116 cells/well testing a narrow dose range (0, 10, 20, 30, 40 and 100 nM) as directed by the 384 well experiment. 72 hours after compound addition viability was assessed using a Vi-cell XR Cell Viability Analyzer (Beckman Coulter) and curves plotted as described above. The IC 30 and IC 50 concentrations obtained from the 6 well experiments were then used for the chemogenomic profiling experiment.
Generation and characterization of the HCT116-Cas9 clone
The Cas9 gene encoding the S. pyogenes CRISPR associated protein 9 RNA-guided DNA endonuclease 
sgRNA library design and construction
The genome-wide sgRNA library targeting 18,360 protein-coding genes was constructed using chipbased oligonucleotide synthesis to generate spacer-tracrRNA-encoding fragments that were PCRamplified and cloned as a pool into the BpiI site of the pRSI16 lentiviral plasmid (Cellecta). The modified tracrRNA scaffold published by Chen et al. 5 was used. Olfactory receptors were omitted from the library. The sgRNA designs were based on published sequences 6 and five sgRNAs were selected per gene targeting the most proximal 5' exons. 277 genes did not have published sgRNA sequence information and new sgRNAs were designed for these targets that contained an NGG PAM motif, filtering for GC content greater than 40% and less than 80%, eliminating homopolymer stretches greater then 4, and removing any guides with off-target locations having fewer than 4 mismatches across the genome. Sequencing of the plasmid pool showed robust normalization with >90% clones present at a representation of +/-5-fold from the median counts in the pool.
Viral Packaging
sgRNA libraries were packaged into lentiviral particles using HEK293T cells as described previously 7 .
Packaging was scaled up by growing cells in CellSTACK flasks (#3313, Corning). For each cell stack, 2.1 e10 7 cells were transfected 24 h after plating using 510.3 µl of TransIT reagent (#MIR2300, Mirus) diluted in 18.4 ml of OPTI-MEM that was combined with 75.6 µg of the sgRNA libraries and 94.5 µg of lentiviral packaging mix (#CPCP-K2A, Cellecta; containing psPAX2 and pMD2 plasmids that encode Gag/Pol and VSV-G, respectively). 72 h post transfection, lentivirus was harvested, aliquoted, and frozen at -80°C. Viral titer was measured using the LentiX qPCR kit (#631235, Clonetech) and was typically in the range of 5.0 e10 6 TU/ml.
Chemogenomic profiling
For the profiling experiment one positive HCT116-Cas9 clone was expanded to 2.0 e10 8 cells and transduced with the lenti-viral sgRNA library (described in detail above) with a coverage of 5 sgRNAs/gene and a multiplicity of infection of 0.5. As described above, the library was designed as two sublibraries each covering 52'000 sgRNAs. Complexity of each subpool was kept always above at least 1000 cells/sgRNA. Each subpool was cultured in 1 CellSTACK flask (#3313, Corning) seeded with 6.7 e10 7 cells on day -1. On day 0 each CellSTACK was infected with one of the subpools. 4
Days after sgRNA infection and continuous selection on puromycin (2 µg/ml), transduction efficiency was assessed by flow cytometry and the experiment only continued if >95% cells were RFP positive.
Cultures of each subpools were then split into 6 CellSTACK flasks at a cell density of 3.5 e10 7 cells.
One day later LB-60-OF61 was added at an IC 30 or IC 50 to both subpool cultures, the control cultures (in duplicates as well) were treated with DMSO only and were used as time-matched controls for the subsequent analysis. DMSO concentration was adjusted to be equal in all cultures. Cultures were propagated and diluted again to 35mio cells when cells reached confluency (usually on day 7,11,14, 18). On day 14, 18 and 21, 7.0 e10 7 cells per condition were harvested and the genomic DNA was extracted using the QIAamp DNA blood maxi kit according to manufacturer's instructions (#51194, Qiagen).
The experiment with reduced sgRNA/cell coverage was conducted as described above with the exception that in the 250 and 125 sgRNA/cell experiments the two subpools were combined and cultured in one CellSTACK flask. Each coverage experiment included a corresponding DMSO control experiment. Cells were split at the same time like the higher coverage experiments but with adjusted splitting ratios.
Determination of relative sgRNA abundance by next generation sequencing
Genomic DNA was quantified using Picogreen (#P11496, Invitrogen) following the manufacturer's recommendations. Illumina sequencing libraries were generated using PCR amplification with primers specific to the genome integrated lentiviral vector backbone sequence. A total of 24 independent PCR reactions were performed per 55,000 sgRNA transduced sample. PCR reactions were performed in a volume of 100 µl, containing a final concentration of 0.5 µM of each PCR primer 
Processing of chemogenomic profiling experiment
Raw sequencing reads were converted to FASTQ format using Illumina bcl2fastq2 (Illumina bcl2fastq2 (Version 2.17.1.14); retrieved from http://support.illumina.com/downloads/bcl2fastq-conversion-software-v217.html). The reads were trimmed to the guide sequence using fastx-toolkit (Gordon, A and Hannon, G. FASTX Toolkit (Version 0.0.13); retrieved from http://hannonlab.cshl.edu/fastx_toolkit/index.html) and the trimmed reads were aligned to the sgRNA sequences in the plasmid library using Bowtie 8 , with no mismatches allowed.
The R software package DESeq2 9 was used to evaluate differential sgRNA representation between the compound treated and the untreated samples. A robust z-score for each sgRNA was calculated using the median and mean-absolute deviation across the log2 fold changes of the library combined results.
To summarize the results at the gene level we applied a methodology derived from siRNA screening analysis named redundant siRNA activity (RSA) analysis 10 . It models the probability of a gene 'hit' Libraries were sequenced in paired-end mode, at a read length of 2 × 200 bp, using the MiSeq platform (Illumina).
The resulting FASTQ files were demultiplexed using the barcoded primers and the demultiplexed FASTQ files were aligned against the human reference genome (GRCh38) using BWA version 0.7. 4 11 with the parameter setting: -t 1 -A 4 -B 16 -O 24 -E 1 -T 120 -L 20 to allow for alignments with long indels. The alignments were then processed by a custom script to extract all putative variants.
Variants that were inconsistent between the two reads of a read pair were excluded. The mutations were then filtered based on the following criteria: The position of the variation had to be within ± 50bp of the sgRNA alignment, the coverage had to be at least 100, the number of reads containing the variation at least 10, and the percentage of reads containing the variation at least 5% of the reads covering the position. The resulting variants were then aggregated into haplotypes based on the reads in which they occurred together. Reads without a variation were assigned to the wild-type (WT)
haplotype. Based on the inspection of the data for the empty wells of the C1 IFC plate, we excluded haplotypes with coverage of less than 2048 for all IFC plates except for the first replicate of day 18
for which we reduced the coverage threshold to 512 due to the low sequencing depth of this experiment. Furthermore, we also excluded haplotypes which contained less than 15% of the reads Table S2 .
Chemical proteomics
For synthesis of the ZA-87-IW08-derivatized resin, 2 ml packed resin volume of NHS-activated sepharose 4 fast flow (#17-0149-01, GE Healthcare) was washed 3 times with 10 ml anhydrous DMSO (#276855, Sigma-Aldrich). 4 or 8 ml of a 0.5 mM solution of ZA-87-IW08 (freshly prepared with anhydrous DMSO) was added to the NHS-activated sepharose resin along with 30 µl triethylamine (#90337, Sigma-Aldrich). The reaction mixtures were vortexed to mix and spun at 100
x g for 2 min. 50 µl aliquots of the supernatants were saved for LC/MS analysis. The reaction mixtures were incubated overnight at room temperature with end-over-end rotating agitation. The following day, the reaction mixtures were spun at 100 x g for 2 min. Again, 50 µl aliquots of the supernatants were saved for LC/MS analysis. Completion of coupling was inferred by loss of starting material following LC/MS analysis. 100 µl of 2-(2-aminoethoxy)ethanol (#A54059, Sigma-Aldrich) was added to the reaction mixtures, vortexed, and allowed to incubate overnight at room temp with end-over-end agitation. Finally, the resins were washed 3 times with 10 ml anhydrous DMSO.
Frozen cell pellets of A2780 cells were gently thawed on ice. Once thawed, the cell pellet was resuspended in Lysis Buffer (50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 5% glycerol (v/v), 1 mM DTT, 0.8% NP40 + 1x HALT Protease Inhibitor Cocktail (#78430, Thermo Scientific)) with a volume that was 2 times the cell pellet volume. After a 30 min incubation on ice, the resuspended cells were subjected to dounce homogenization with 10 strokes of the tight fitting pestle and the resulting lysate was centrifuged at 800 x g for 10 min at 4°C. The supernatant (S0.8 fraction)
was collected and saved. The pellet (P0. washed with 3 ml Wash Buffer 2, 1.5 ml Wash Buffer 2, followed by 1.5 ml Wash Buffer 1 (50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 1 mM DTT). To elute bound proteins, 50 µl 2x LDS sample buffer (NuPAGE) + 10 mM DTT was added to each sample, which were incubated at 55 °C for 30 min. Eluted proteins were separated from resin by centrifugation (14,000 x g for 2 min at room temp). Proteins were alkylated with 200 mg/ml iodoacetamide for 30 min.
Proteins were subjected to in-solution trypsinization over night at 37ºC followed by isobaric labelling using iTRAQ 4plex reagents (#4466096, AB Sciex) using 114/115/116 for 100/10/1 µM ND-37- http://tools.proteomecenter.org/software.php) using a false positive threshold of <1% for protein identifications and removing obvious contaminants. For each peptide sequence and modification state, reporter ion signal intensities from all spectral matches were summed for each reporter ion type and corrected according to the isotope correction factors given by the manufacturer. Only peptides unique to a given protein within the total dataset of identified proteins were used for relative protein quantification. Peptide fold changes were calculated (treatment over DMSO control) and subsequently renormalized within each replicate analysis using the median fold change of all quantified peptides to compensate for differences in total protein yield for each affinity purification. Protein fold changes were calculated as median peptide fold change and p-values were calculated using a one-way T-test Full dose response quantitative proteomics data for all proteins quantified in the two experiments are given in Supplemental Table S3 .
Supplemental Figure S1 . Gel-analysis of lysates from chemoproteomics experiments. A) ZA-87-IW08 and ND-37-YO30 used in the chemoproteomics experiments; for ZA-87-IW08 the actual affinity resin after immobilization on NHS-activated sepharose is depicted. B) Gel separation of 10% of each individual pulldown material identifies a strongly enriched protein in the 55kDa range (arrow) that shows visible competition with free ND-37-YO30. The molecular weight of the band corresponds to that of NAMPT (55521 Da). Taken together with the fact that NAMPT is among the most abundant proteins in the pulldown material based on semi-quantitative spectrum count (see Table S3 ), these data indicate that he ZA-87-IW08-based resin is able to strongly enrich functional NAMPT protein.
C) Densiometric analysis of the bands from panel B. Decreasing intentsties of the NAMPT bands in presence of increasing concentrations of ND-37-YO30 indicates dose responsive competition by ND-37-YO30 across the two replicates.
NAD rescue experiment
Serially diluted compound (1:2 dilution factor) was dispensed into 384 well plates containing 1'500 cells/well prefilled with 40 µl growth medium containing supplemented with or without 10 µM nicotinic acid (#N4126, Sigma-Aldrich). The experiment was set up to obtain triplicate data points.
Plates were incubated for 48 hours followed by cell viability determination using CellTiter-Glo (#G7570, Promega) according to manufacturer instructions.
Identification of resistance conferring mutations in NAMPT
The cDNA of wildtype or H191R mutant NAMPT was cloned into a pLENTI6-derived expression construct (#V49610, ThemrmoFischer Scientific) under control of the doxycycline-inducible promoter and packaged into infectious viral particles. Cells were transduced at a multiplicity of infection (M.O.I.) of 0.5 and selected on blasticidin. Blasticidin-resistant cells were seeded into 384 well plates at a density of 8000 cells/well prefilled with 90 µl/well growth medium (RPMI+10%FBS+Pen/Strep). Serially diluted compound (1:2.5 dilution factor) was dispensed and to a subset of plates 5ug/ml doxycycline added. The experiment was set up to obtain triplicate data points. Plates were incubated for 72 hours followed by cell viability determination using CellTiterGlo (#G7570, Promega) according to manufacturer instructions.
In silico docking approaches
LB-60-OF61 was analyzed for its potential to engage the catalytic pocket of the published NAMPT crystal structure (PDB code : 2GVJ 12 ) by in silico docking approaches the using the Glide program 
